Robeco Institutional Asset Management B.V. Purchases 151,283 Shares of Alkermes plc $ALKS

Key Points

• Robeco Institutional Asset Management B.V. increased its stake in Alkermes by 112.6% in Q4, buying 151,283 shares to hold 285,670 shares (about 0.17% of the company) valued at roughly $7.99 million.
• Insiders have been net sellers recently, disposing of 159,468 shares valued at $5.43 million in the past 90 days, including SVP Christian Todd Nichols (6,000 shares) and EVP David Gaffin (2,034 shares).
• Analysts show a consensus "Moderate Buy" rating with a $44.07 price target amid mixed upgrades (e.g., Wells Fargo and Truist) while ALKS trades around $33.22 with a market cap near $5.5 billion.

Robeco Institutional Asset Management B.V. raised its position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 112.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 285,670 shares of the company's stock after acquiring an additional 151,283 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.17% of Alkermes worth $7,993,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of ALKS. Baker BROS. Advisors LP increased its position in Alkermes by 26.2% during the third quarter. Baker BROS. Advisors LP now owns 8,091,351 shares of the company's stock valued at $242,741,000 after acquiring an additional 1,680,748 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its position in Alkermes by 1,070.6% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,208,944 shares of the company's stock valued at $36,268,000 after acquiring an additional 1,105,666 shares during the last quarter. BNP Paribas Financial Markets increased its position in Alkermes by 787.2% during the second quarter. BNP Paribas Financial Markets now owns 1,135,478 shares of the company's stock valued at $32,486,000 after acquiring an additional 1,007,488 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Alkermes during the third quarter valued at $27,040,000. Finally, American Century Companies Inc. increased its position in Alkermes by 20.2% during the third quarter. American Century Companies Inc. now owns 4,397,471 shares of the company's stock valued at $131,924,000 after acquiring an additional 740,248 shares during the last quarter. Institutional investors own 95.21% of the company's stock.

Insider Buying and Selling at Alkermes

In related news, SVP Christian Todd Nichols sold 6,000 shares of the company's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $30.00, for a total value of $180,000.00. Following the completion of the sale, the senior vice president directly owned 109,769 shares of the company's stock, valued at $3,293,070. This represents a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David Joseph Gaffin sold 2,034 shares of the company's stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $34.57, for a total transaction of $70,315.38. Following the completion of the sale, the executive vice president directly owned 233,592 shares of the company's stock, valued at approximately $8,075,275.44. This trade represents a 0.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 159,468 shares of company stock valued at $5,433,699 in the last ninety days. 4.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ALKS has been the topic of a number of analyst reports. Wells Fargo & Company boosted their price objective on shares of Alkermes from $37.00 to $43.00 and gave the company an "overweight" rating in a research report on Thursday, February 26th. Wall Street Zen lowered shares of Alkermes from a "buy" rating to a "hold" rating in a research note on Saturday, February 28th. Piper Sandler lowered their target price on shares of Alkermes from $45.00 to $43.00 and set an "overweight" rating for the company in a research note on Tuesday, March 24th. Truist Financial raised shares of Alkermes to a "strong-buy" rating in a research note on Wednesday, March 25th. Finally, HC Wainwright reissued a "neutral" rating and set a $43.00 target price on shares of Alkermes in a research note on Thursday, February 26th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $44.07.

Alkermes Trading Down 1.9%

Shares of ALKS opened at $33.22 on Thursday. The firm has a market capitalization of $5.52 billion, a P/E ratio of 23.23 and a beta of 0.44. Alkermes plc has a 12-month low of $25.17 and a 12-month high of $36.48. The firm has a fifty day moving average price of $31.39 and a 200-day moving average price of $30.73.

Alkermes (NASDAQ:ALKS - Get Free Report) last issued its earnings results on Saturday, February 14th. The company reported $0.29 earnings per share (EPS) for the quarter. The firm had revenue of $384.55 million during the quarter. Alkermes had a net margin of 16.37% and a return on equity of 14.91%. Analysts predict that Alkermes plc will post 1.31 earnings per share for the current year.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes' portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes' commercial franchise features several approved products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.